Tumor Biology

, Volume 37, Issue 1, pp 447–453 | Cite as

Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma

  • Huanxi Xu
  • Yuqi Yang
  • Hongmei Zhao
  • Xuguang Yang
  • Yu Luo
  • Yinxiang Ren
  • Wei Liu
  • Ning Li
Research Article


Deregulation of microRNAs (miRNAs) is essential to tumor development, and serum miRNA profiles have been reported in several cancers. However, the serum miRNA profile in oral squamous cell carcinoma (OSCC) remained unclear. The present study aimed to explore abnormal miRNA profile in sera samples from OSCC patients and the association of miR-483-5p with patient prognosis. Microarray analysis was performed in sera from OSCC patients versus healthy controls. miR-483-5p expression was measured by reverse transcription (RT)-PCR and correlated to clinicopathological characteristics of OSCC patients. The prognostic significance was then evaluated with a Kaplan–Meier curve and log-rank tests, using a Cox proportional hazard model. According to microRNA array, 16 miRNAs were upregulated and 10 were downregulated in OSCC patient sera. miR-483-5p expression was significantly increased in OSCC patients (3.23-fold, p < 0.01), and this was significantly correlated with tumor nodal metastasis (TNM) stage and lymph nodal metastases (p < 0.01, p < 0.01). For predicting OSCC, receiver operating characteristic (ROC)/area under the curve (AUC) analysis confirmed a AUC of 0.85 (sensitivity of 0.853 and specificity of 0.746). OSCC patients with high serum miR-483-5p had lower survival than those with low expression, and multivariate analyses for overall survival revealed that high serum miR-483-5p expression was an independent prognostic factor for OSCC (HR = 2.32, 95 %CI 1.20–4.48). miR-483-5p expression increased in OSCC patient sera, and this may be a novel diagnostic and prognostic biomarker for OSCC.


Oral squamous cell carcinoma microRNA miR-483-5p Prognosis Overall survival 



We thank LetPub ( for its linguistic assistance during the preparation of this manuscript.

Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Warnakulasuriya S. Squamous cell carcinoma and precursor lesions: prevention. Periodontol. 2011;2000(57):38–50.CrossRefGoogle Scholar
  3. 3.
    Gupta K, Metgud R. Evidences suggesting involvement of viruses in oral squamous cell carcinoma. Patholog Res Int. 2013;2013:642496.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol. 2007;43:523–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: the past 20 years. Oral Oncol. 2012;48:383–92.CrossRefPubMedGoogle Scholar
  9. 9.
    Ries J, Vairaktaris E, Kintopp R, Baran C, Neukam FW, et al. Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo. 2014;28:851–61.PubMedGoogle Scholar
  10. 10.
    Ries J, Vairaktaris E, Agaimy A, Kintopp R, Baran C, et al. miR-186, miR-3651 and miR-494: potential biomarkers for oral squamous cell carcinoma extracted from whole blood. Oncol Rep. 2014;31:1429–36.PubMedGoogle Scholar
  11. 11.
    Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34:219–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Qu X, Zhao M, Wu S, Yu W, Xu J, et al. Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol. 2014;31:219.CrossRefPubMedGoogle Scholar
  13. 13.
    Zheng XH, Cui C, Ruan HL, Xue WQ, Zhang SD, et al. Plasma microRNA profiling in nasopharyngeal carcinoma patients reveals miR-548q and miR-483-5p as potential biomarkers. Chin J Cancer. 2014;33:330–8.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Yoon AJ, Wang S, Shen J, Robine N, Philipone E, et al. Prognostic value of miR-375 and miR-214-3p in early stage oral squamous cell carcinoma. Am J Transl Res. 2014;6:580–92.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–33.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Huanxi Xu
    • 1
  • Yuqi Yang
    • 2
  • Hongmei Zhao
    • 3
  • Xuguang Yang
    • 4
  • Yu Luo
    • 5
  • Yinxiang Ren
    • 6
  • Wei Liu
    • 5
  • Ning Li
    • 1
  1. 1.Department of StomatologyShihua General Hospital of LanzhouGansuChina
  2. 2.Department of EndodonticsLanzhou Stomatology HospitalGansuChina
  3. 3.Department of OrthodonticsLanzhou Stomatology HospitalGansuChina
  4. 4.Institute of Anatomy and Embryology, School of Basic Medical SciencesLanzhou UniversityLanzhouChina
  5. 5.Institute of Pathophysiology, School of Basic Medical SciencesLanzhou UniversityLanzhouChina
  6. 6.Institute of Pathology, School of Basic Medical SciencesLanzhou UniversityLanzhouChina

Personalised recommendations